Shots:
- The EC has approved the Arexvy RSV vaccine for adults ≥18 yrs in Europe. While it was previously authorized only for adults ≥50 yrs at risk
- The adjuvanted RSV vaccine includes a stabilized form of a protein from the respiratory syncytial virus (RSV), called the prefusion F protein (RSVPreF3), combined with GSK’s AS01E adjuvant, which enhances immune response. The AS01E adjuvant contains STIMULON QS-21, a plant-derived ingredient licensed from Antigenics (Agenus).
- GSK is pursuing broader approvals for its RSV vaccine in regions such as the US and Japan
Ref: GSK | Image: GSK | Press Release
Related News: GSK and Shionogi Restructure ViiV Healthcare Ownership as Pfizer Exits
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
